Basaglar Injection, Solution
Product Images NDC 0002-7715

Product Visual Gallery

This gallery contains 37 technical images submitted to the FDA as part of the official labeling for Basaglar (NDC 0002-7715). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Eli Lilly And Company, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Basaglar Chem Struct)

Chemical structure diagram showing the A and B chains of a peptide or protein, with amino acid residues labeled and connected by disulfide bonds. The diagram includes sequence and structural relationships among residues, with an extended chain segment illustrated below the B chain.*

FDA Label Image

Figure (Basaglar Kpen 80u Ifu 1 V3)

BASAGLAR Tempo Pen in 100 units/mL strength, designed for subcutaneous injection. The pen is white with a clear dosage window showing an adjustable dose dial. The label indicates it contains insulin glargine and is intended for single patient use only. The product is manufactured by Eli Lilly and Company.*

FDA Label Image

Figure (Basaglar Kpen 80u Ifu 2a V3)

An annotated diagram showing the parts of the BASAGLAR Tempo Pen insulin delivery device. The components labeled from left to right include the Pen Cap with Cap Clip, Rubber Seal, Cartridge Holder, Plunger, Pen Body with attached Label, Dose Window, Dose Indicator, and Dose Knob.*

FDA Label Image

Figure (Basaglar Kpen 80u Ifu 2b V2)

An instructional diagram showing parts of a pen needle and a dose knob. The pen needle parts include the outer needle shield, inner needle shield, paper tab, and needle (not included). The dose knob is depicted with a green ring.*

FDA Label Image

Figure (Basaglar Pen Ifu 3 V1)

An instructional diagram showing a BASAGLAR Tempo Pen needle with a red arrow pointing left, likely indicating needle removal or attachment direction for the 100 IU/mL insulin pen by Eli Lilly and Company.*

FDA Label Image

Figure (Basaglar Kpen Ifu 4 V1)

BASAGLAR Tempo Pen label showing the insulin delivery pen with a dialed dose window. The image illustrates the pen's dose indicator marking with a red circle highlighting the dose setting area. The label is from Eli Lilly and Company for the 100 IU/mL strength.*

FDA Label Image

Figure (Basaglar Pen Ifu 5 V1)

Illustration showing a hand twisting and removing the cap from a pen device, indicated by a red arrow suggesting the direction of the twist. This likely represents part of the preparation steps for the BASAGLAR Tempo Pen, a 100 [iU]/mL insulin pen by Eli Lilly and Company.*

FDA Label Image

Figure (Basaglar Pen Ifu 6 V1)

An instructional illustration showing a BASAGLAR Tempo Pen needle covered with a protective cap and a red arrow indicating the removal of the cap by twisting. This image highlights the step to prepare the pen before injection.*

FDA Label Image

Figure (Basaglar Pen Ifu 7 V1)

An instructional diagram showing how to dispose of the BASAGLAR Tempo Pen needle. It depicts the needle cap labeled 'Keep' with an arrow pointing left, and the needle being removed from the pen, labeled 'Throw Away.' This likely instructs users to keep the needle cap and discard the needle after use.*

FDA Label Image

Figure (Basaglar Kpen Ifu 8 V1)

Illustration showing a close-up view of an insulin pen dosage selector with a red arrow indicating the action of pressing or adjusting a part of the device, likely for dose setting or administration. This is relevant to the BASAGLAR Tempo Pen 100 IU/mL by Eli Lilly and Company.*

FDA Label Image

Figure (Basaglar Pen Ifu 9 V1)

An instructional illustration showing hands holding a BASAGLAR Tempo Pen insulin injector. One hand supports the pen while the other hand uses fingers to manipulate or check the dose window or dial.*

FDA Label Image

Figure (Basaglar Kpen Ifu 10 V1)

Instructional diagram showing a hand holding a BASAGLAR Tempo Pen insulin injector. The image highlights the tip of the pen with a zoomed-in circle indicating how to align or remove the pen cap or needle cover, with a red arrow pointing upward to suggest the direction of movement.*

FDA Label Image

Figure (Basaglar Kpen Ifu 11 V1)

An instructional illustration showing a close-up view of the dose window on a BASAGLAR Tempo Pen, highlighting the display of insulin units for adjustable dosing.*

FDA Label Image

Figure (Basaglar Kpen Ifu 12 V1)

Instructional illustration showing a hand holding a BASAGLAR Tempo Pen insulin injector. It depicts a step in preparing the pen for injection, focusing on the dosage window with an arrow pointing upward, indicating dial adjustment or dose selection.*

FDA Label Image

Figure (Basaglar Kpen 80u Ifu 13 V2)

An instructional diagram showing a detailed view of a BASAGLAR Tempo Pen dosage window, highlighting the dose number '12'. The illustration focuses on the pen's dose display for accurate dose selection.*

FDA Label Image

Figure (Basaglar Inj Sites)

An anatomical illustration showing recommended BASAGLAR Tempo Pen injection sites on a human figure from both front and back views. Injection areas are marked on the abdomen, outer upper arms, front and outer sides of thighs, and the upper buttocks.*

FDA Label Image

Figure (Basaglar 5sec Clock)

An illustration showing a stopwatch with the hand pointing at 5 seconds and the number '5 sec' displayed inside, indicating a timing instruction to wait for 5 seconds.*

FDA Label Image

Figure (Basaglar Kpen Ifu 22 V1)

An instructional illustration showing a hand holding a BASAGLAR Tempo Pen injecting into the abdomen of a person. The image highlights the injection technique for subcutaneous administration using the pen device.*

FDA Label Image

Figure (Basaglar Pen Ifu 13 V1)

An instructional illustration showing a hand holding a BASAGLAR Tempo Pen insulin injector pen, with an arrow indicating the removal of the pen cap, demonstrating the first step in preparing the pen for injection.*

FDA Label Image

Figure (Basaglar Pen Ifu 14 V1)

Instructional illustration showing a hand holding a BASAGLAR Tempo Pen with an orange ribbon wrapped around the needle area, likely demonstrating a step in pen use or preparation. The pen is depicted in outline style without visible text details.*

FDA Label Image

Figure (Basaglar Kpen Ifu 21 V1)

An instructional diagram showing the BASAGLAR Tempo Pen, an insulin delivery device. The illustration depicts the pen with a protective cap to be removed by pulling it off in the direction indicated by a red arrow pointing to the left.*

FDA Label Image

Figure (Basaglar Qr)

FDA Label Image

Figure (Basaglar Tpen Ifu 1 V3)

BASAGLAR Tempo Pen 100 units/mL is a pre-filled insulin glargine pen injector by Eli Lilly and Company. The label indicates a single-patient use with a dosage display window showing the number 0. The pen includes dose adjustment markings and a removable cap at the injection end.*

FDA Label Image

Figure (Basaglar Tpen Ifu 2 V4)

An illustration showing the parts of the BASAGLAR Tempo Pen insulin injection device. Visible components are the Pen Cap with Cap Clip, Cartridge Holder with Rubber Seal, Plunger, Pen Body with label indicating Basaglar Tempo Pen and insulin glargine injection, Dose Indicator with Dose Window, and Dose Knob for adjusting dosage.*

FDA Label Image

Figure (Basaglar Tpen Ifu 3 V1)

An illustration diagram showing parts of a pen needle assembly for BASAGLAR Tempo Pen, including the outer needle shield, inner needle shield, needle, and paper tab. Also depicted is a separate dose knob component used to set dosage.*

FDA Label Image

Figure (Basaglar Tpen Ifu 4 V1)

An instructional diagram showing a BASAGLAR Tempo Pen insulin injector. The image highlights the dosage selector window with visible dose increment markings, emphasizing the adjustment mechanism on the pen device by Eli Lilly and Company.*

FDA Label Image

Figure (Basaglar Tpen Ifu 5 V1)

Instructional diagram showing a close-up of the dose selector window and dose knob on the BASAGLAR Tempo Pen insulin delivery device. The image highlights the dose setting mechanism with an arrow indicating where to turn or adjust the knob.*

FDA Label Image

Figure (Basaglar Tpen Ifu 6 V1)

An instructional line drawing showing a person holding a BASAGLAR Tempo Pen insulin injector. The illustration highlights the 'Dose Knob' with a zoomed-in circular inset, demonstrating the dosage setting mechanism. An arrow below the pen indicates the direction of dose adjustment or injection.*

FDA Label Image

Figure (Basaglar Tpen Ifu 7 V1)

An illustration showing the dose window of a BASAGLAR Tempo Pen insulin delivery device. The window displays the numerical dose indicator markings at 0 and 10 units with a red dose pointer, and the dose adjustment knob is visible on the right side of the image.*

FDA Label Image

Figure (Basaglar Tpen Ifu 8 V1)

An instructional illustration showing a hand holding a Basaglar Tempo Pen insulin injector. The image depicts the thumb pressing or sliding a button with a large red arrow pointing upward, indicating an action to be performed, likely related to dose adjustment or injection operation.*

FDA Label Image

Figure (Basaglar Tpen Ifu 9 V2)

An instructional diagram showing a close-up view of the BASAGLAR Tempo Pen dose window. The image highlights the dose number display, which currently shows the number 12, with an arrow pointing to the dose setting indicator on the pen dial.*

FDA Label Image

Figure (Basaglar Tpen Ifu 10 V2)

An instructional diagram showing a close-up view of a Basaglar Tempo Pen dose window and dose selector dial. The dose window displays the selected units, with numerical values visible, while a red arrow points specifically at the dose amount. Dosage increments on the dial range from 2 to 8 units, illustrating dose adjustment.*

FDA Label Image

Figure (Basaglar Tpen Ifu 12 V1)

Instructional illustration showing a person administering an injection with a BASAGLAR Tempo Pen. The image depicts the pen needle inserted into the skin of the abdomen, with one hand holding the pen and the other pinching the skin. An arrow indicates pressing the pen to deliver the dose.*

FDA Label Image

Figure (Basaglar Tpen Ifu 14 V1)

An instructional line drawing showing the BASAGLAR Tempo Pen insulin device with a protective cap removed and an arrow indicating the direction of cap removal. The pen is depicted horizontally with measurement markings visible on its body.*

FDA Label Image

Figure (Basaglar Kpen 80u Ifu 15 V2)

An illustration showing a close-up of the dose window and dose selector of a Basaglar Tempo Pen insulin injector. The dose numbers 24 and 26 are visible in the window, with a red arrow pointing to 26 on the dose selector knob, which is marked with increments 2, 4, 6, and 8 units.*

FDA Label Image

Package Carton – Basaglar Kwikpen (Basaglar Kpen 80u Carton 033 01)

Label for Basaglar KwikPen insulin glargine injection, 100 units per mL (U-100), 5 x 3 mL prefilled pens. The label states it is for single patient use only, subcutaneous injection, and includes storage instructions and manufacturer details from Eli Lilly and Company. The packaging warns to discard unused portions 28 days after opening and specifies no needles are included.*

FDA Label Image

Package Carton – Basaglar Tempo Pen (Basaglar Tpen 80u Carton 046 01)

Packaging label for Basaglar Tempo Pen (insulin glargine) injection, 100 units per mL (U-100), indicated for subcutaneous use only. The label specifies that it is for single patient use and contains 5 prefilled pens of 3 mL each. Manufactured by Eli Lilly and Company, the label includes storage instructions, ingredient details, and a barcode with NDC 0002-8214-05.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.